1. Home
  2. FUSB vs ACET Comparison

FUSB vs ACET Comparison

Compare FUSB & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First US Bancshares Inc.

FUSB

First US Bancshares Inc.

N/A

Current Price

$15.97

Market Cap

84.4M

Sector

Finance

ML Signal

N/A

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$8.27

Market Cap

77.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FUSB
ACET
Founded
1952
1947
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
84.4M
77.3M
IPO Year
1995
2017

Fundamental Metrics

Financial Performance
Metric
FUSB
ACET
Price
$15.97
$8.27
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$48.33
AVG Volume (30 Days)
6.1K
140.4K
Earning Date
05-04-2026
05-06-2026
Dividend Yield
1.77%
N/A
EPS Growth
N/A
N/A
EPS
1.00
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$15.83
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.47
$0.46
52 Week High
$16.08
$9.05

Technical Indicators

Market Signals
Indicator
FUSB
ACET
Relative Strength Index (RSI) 63.01 62.09
Support Level $14.73 $6.28
Resistance Level $15.99 $8.34
Average True Range (ATR) 0.16 0.49
MACD 0.03 0.19
Stochastic Oscillator 86.27 83.03

Price Performance

Historical Comparison
FUSB
ACET

About FUSB First US Bancshares Inc.

First US Bancshares Inc is a bank holding company. The Bank conducts general commercial banking business and offers banking services such as demand, savings, individual retirement account and time deposits, personal and commercial loans, safe deposit box services, and remote deposit capture. The Bank provides a range of commercial banking services to small and medium-sized businesses, property managers, business executives, professionals, and other individuals.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).

Share on Social Networks: